ADA26: Kidney disease analysis given spotlight
Study data, including real-world analysis, for kidney disease were presented at ADA 2026.
Therapy Area
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies
Argenx’s Vyvgart shows durability in myositis and Sjögren’s
EMA and AMA collaborate on Ebola trials amid public health emergency
Rezolute’s stock up on interim Phase III tumour HI data
ASCO26: In vivo oncology approaches continue to show promise
